Cat’s Claw, Graviola and Effects on Cancer
What is cat’s claw? Just about everyone has dealt with cancer in one way or another. Numerous cancer patients are dealing with conventional methods, and several are focusing on alternative methods in order to lessen their diagnosis. These two effective rainforest herbs may stimulate the appropriate systems to help provide cancer a knock-out punch.
Cat’s claw, additionally referred to as una de gato, is a robust, woody vine which thrives within the Amazon rainforest. It’s name comes from hook-like thorns which grow throughout the vine and match that of the claws of a cat.
It has numerous groups of plant chemicals which make up its action, the most researched group being oxidole alkaloids, which have been attested to provide immune-stimulant and anti-leukemic qualities. Cat’s claw has been made use of throughout Europe and Peru during the 1990s as an adjudicative solution for cancer, as well as for additional diseases that concentrate on the immune system.
Further investigation on cat’s claw which sustain its positive results in opposition towards cancer includes:
- In 1998, Swedish researchers noted that it lessened the expansion of lymphoma and leukemia cells in vitro.
- In 2001, Italian scientists reported in vitro study in which cat’s claw directly lessened the expansion of a human breast cancer cell line by 90%.
- Documentation on Keplinger’s observatory trials displayed that individuals afflicted with cancer utilizing cat’s claw along with conventional treatments, such as chemotherapy and radiation, reported a drop in side effects such as loss of weight, loss of hair, nausea and secondary infections.
- Subsequent researchers have documented that cat’s claw may help assist in DNA cellular repair as well as keep cells from mutating, and may furthermore assist in the prevention of loss of white blood cells and immune cell damage brought about by numerous chemotherapy medications.
Furthermore, cat’s claw has been documented to wipe-out many viruses, decrease free radicals and lessen inflammation.
A group of chemicals referred to as Annonaceous acetogenins, discovered within the stem, leaf bark as well as the seeds within graviola have been verified by 3 individual research teams to have substantial anti-tumorous qualities in addition to selective toxicity in opposition towards a variety of cancer cells (without causing damage to otherwise healthy cells), at extremely low doses.
Research and investigation upon graviola which document its positive effect in opposition towards cancer includes:
- Purdue University in 97′ publicized data which discovered that this novel group of elements within graviola not only are successful in eliminating tumors which have proven immune to anti-cancer treatments, but additionally appear to display an affinity for such resistant cells. This signifies that those particular cells that display multi-drug resistance (MDR) can in effect be eliminated by acetogenins, with documents that they advantageously eliminated MDR cells by obstructing the transportation of ATP — the primary origin of cellular energy — into them.
- During a plant-screening program in 1976 by the National Cancer Institute, graviola leaves and stems displayed toxicity in opposition towards cancer cells, as well as particular acetogenins have been reported to be selectively toxic in vitro to these forms of tumor cells: lung carcinoma, human breast, prostate adenocarcinoma, pancreatic carcinoma, colon adenocarcinoma, liver cancer cell lines, human lymphoma and MDR human breast adenocarcinoma.
- In 2003, Taiwan scientists reported that the primary graviola acetogenin, annonacin, was extremely toxic to ovarian, breast, cervical, bladder, as well as skin cancer at very minimal dosages.
Additionally, graviola has been recognized to eliminate bacteria, parasites and viruses in addition to motivate digestion and lessen symptoms associated with depression.
Taylor, Leslie, ND. The Healing Power of Rainforest Herbs: A Guide to Understanding and Using Herbal Medicinals. Garden City Park, NY: Square One, 2005. Print.